According to the initial results just released by Eli Lilly, a once weekly Dulaglutide achieved the primary goal of non-inferiority to the highest approved dose of Victoza (administered once daily) in a 26 week study including 599 patients. Dulaglutide, chemically known as liraglutide, belongs to a class of drugs called GLP-1 receptor antagonists. They are known to decrease blood glucose levels by increasing the release of insulin after meals and by slowing the absorption of food from the gastrointestinal tract. Eli Lilly and Co is hoping to have approval this year since Dulaglutide is condisered one of the most important drugs in Lilly’s pipeline for drug development.
How often do you address the lack of compliance as a primary issue in your interactions with patients with diabetes? What are your thoughts on this new agent?
For additional information please see Reuters.
Image courtesy of [Carlos Porto]/freedigitalphotos.net